| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S8756-3282(98)00193-8 |
| P698 | PubMed publication ID | 10221550 |
| P2093 | author name string | P D Delmas | |
| P Miossec | |||
| P Garnero | |||
| N Buchs | |||
| P Jouvenne | |||
| P2860 | cites work | The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 |
| Iliac crest trabecular bone mass and structure in patients with non-steroid treated rheumatoid arthritis | Q33560469 | ||
| Urinary excretion of the hydroxypyridinium cross links of collagen in patients with rheumatoid arthritis | Q33561920 | ||
| Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis | Q33566017 | ||
| Bone turnover in non-steroid treated rheumatoid arthritis | Q33566166 | ||
| Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis | Q33578499 | ||
| Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis | Q33578907 | ||
| Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro | Q41491080 | ||
| Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films | Q41513883 | ||
| Marked diurnal variation in urinary excretion of pyridinium cross-links in premenopausal women | Q43591804 | ||
| Immunoassay for urinary pyridinoline: the new marker of bone resorption | Q46069864 | ||
| Increased levels of urinary collagen crosslinks in females with rheumatoid arthritis. | Q51600364 | ||
| Lower mobility and markers of bone resorption in the elderly. | Q51616255 | ||
| Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. | Q54784059 | ||
| Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption | Q60777504 | ||
| The Effect of Glucocorticoids on Joint Destruction in Rheumatoid Arthritis | Q61912636 | ||
| A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine | Q67967023 | ||
| Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay | Q67986101 | ||
| Bone remodeling in osteoporosis associated with rheumatoid arthritis | Q68032435 | ||
| Collagen cross-linking amino acids | Q69236769 | ||
| Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis | Q71644718 | ||
| Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy | Q71880208 | ||
| Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylprednisolone | Q72177611 | ||
| The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption: the effect of nandrolone decanoate and hormone replacement therapy | Q72269396 | ||
| Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis | Q72373650 | ||
| The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women | Q72607840 | ||
| Generalised bone loss in patients with early rheumatoid arthritis | Q72682386 | ||
| Transient decrease in osteocalcin and markers of type 1 collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis | Q72920159 | ||
| The determination of pyridinium crosslinks in urine and serum as a possible marker of cartilage degradation in rheumatoid arthritis | Q73203801 | ||
| Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen | Q73451989 | ||
| Therapeutic criteria in rheumatoid arthritis | Q80386526 | ||
| P433 | issue | 4 | |
| P921 | main subject | rheumatoid arthritis | Q187255 |
| P304 | page(s) | 381-385 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Bone | Q15755003 |
| P1476 | title | Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products | |
| P478 | volume | 24 |
| Q36392269 | A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab |
| Q27687777 | Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities |
| Q39035413 | Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease |
| Q33767025 | Catabolic and anabolic periarticular bone changes in patients with rheumatoid arthritis: a computed tomography study on the role of age, disease duration and bone markers |
| Q37679653 | Could biomarkers of bone, cartilage or synovium turnover be used for relapse prediction in rheumatoid arthritis patients? |
| Q93640889 | EULAR and its journal |
| Q24796830 | Hormone replacement therapy, calcium and vitamin D3 versus calcium and vitamin D3 alone decreases markers of cartilage and bone metabolism in rheumatoid arthritis: a randomized controlled trial [ISRCTN46523456] |
| Q37202023 | IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion |
| Q90531768 | Laboratory aspects and clinical utility of bone turnover markers |
| Q33844059 | Low bone-mineral density in patients with HIV: pathogenesis and clinical significance |
| Q35550491 | Markers of joint destruction: principles, problems, and potential |
| Q24817123 | Osteoporosis in experimental postmenopausal polyarthritis: the relative contributions of estrogen deficiency and inflammation |
| Q37307876 | Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy. |
| Q34896346 | Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4 years after diagnosis. |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q37315782 | Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY |
| Q85029033 | Serum biomarker levels for musculoskeletal disease in two‐ and three‐year‐old racing Thoroughbred horses: A prospective study of 130 horses |
| Q46121066 | Serum concentrations of formation (PINP) and resorption (Ctx) bone turnover markers in rheumatoid arthritis |
| Q37801555 | Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis |
| Q37067708 | The anti-arthritic and immune-modulatory effects of NHAG: a novel glucosamine analogue in adjuvant-induced arthritis. |
| Q39385131 | Use of CTX-I and PINP as bone turnover markers: National Bone Health Alliance recommendations to standardize sample handling and patient preparation to reduce pre-analytical variability |
| Q36231859 | Validation of new biomarkers in systemic autoimmune diseases |
| Q54940924 | Yi Shen Juan Bi Pill Ameliorates Bone Loss and Destruction Induced by Arthritis Through Modulating the Balance of Cytokines Released by Different Subpopulations of T Cells. |
Search more.